Planning lab space is one of the most consequential decisions a growing life sciences company will make, because laboratory facilities shape science, recruiting, and capital efficiency all at once.
Why Lab Portfolio Planning Differs from Conventional Real Estate Strategy
Life sciences real estate operates on a fundamentally different logic than general commercial occupancy. The physical environment is not a backdrop for work — it is part of the scientific process. Power density, HVAC redundancy, wet lab sinks per bench, and cold storage footprint are not amenities; they are operational requirements that determine whether research can proceed at all.
The time horizons compound the complexity. Drug discovery programs often run five to ten years, while early-stage companies frequently sign three-to-five-year leases in incubator settings to preserve capital. The mismatch between research duration and lease term means that portfolio strategy must plan for multiple transition points that will occur under scientific and financial uncertainty.
Because of this, the question of How to Plan Lab Portfolio Strategy for a Growing Life Sciences Company cannot be answered by applying standard square-footage-per-head ratios. The methodology has to account for wet lab yield, equipment loads, regulatory inspection readiness, and the possibility that a clinical milestone will require rapid expansion or contraction within a single budget cycle.
Defining the Strategic Intent Before You Scout Space
Any credible portfolio strategy starts with a clear articulation of intent: what stage is the science, how many programs are active, which programs are likely to advance or be deprioritized, and over what horizon. Without this clarity, a real estate team will evaluate buildings against criteria that do not reflect the actual operating model.
A Stage 1 discovery organization running two to three programs in parallel needs a different space profile than a Stage 3 company preparing for commercial manufacturing and GxP compliance. The former can often function in shared incubator or accelerator space with flexible licensing terms. The latter needs dedicated facility control, validated HVAC, and the ability to manage access under regulatory scrutiny.
A useful tool here is a program-weighted square footage model. For each active program, estimate the bench space, equipment footprint, dedicated storage, and clean room or BSL-2 requirement. Apply a probability weight to each program based on its likelihood of advancing to the next phase within the planning horizon. The resulting weighted demand figure gives a realistic range — not a single number — that should frame all subsequent site selection decisions.
This intent-setting phase should also produce a rough financial envelope. What is the company's projected cash runway, and how many months of real estate operating cost does the board consider acceptable as a percentage of burn? That ratio will set a ceiling on the quality tier of space the company should target, independent of what the science would ideally require.
Building the Site Selection Criteria Framework
With intent defined, the next step is constructing a weighted scoring framework for site selection. This is not a qualitative shortlist exercise; it is a structured evaluation that attaches a numerical weight to each operational criterion and forces discipline in the comparison of competing options.
The criteria set for life sciences site selection typically spans four categories. The first is technical specifications: power capacity in kilowatts per square foot, HVAC system type and redundancy, floor-to-floor height, slab loading, and the presence of existing vivarium, clean room, or cGMP infrastructure. The second is location factors: proximity to the talent pool, distance to partner institutions or CROs, and accessibility by public transit for shift workers.
The third category is lease economics: effective rent, tenant improvement allowance, free rent periods, and the landlord's willingness to fund specialized build-out. The fourth is optionality: does the building offer contiguous expansion space, and does the landlord have adjacent buildings in the same campus where a right of first offer could be negotiated? Each criterion receives a weight, and each candidate property receives a score within each criterion. The weighted total produces a defensible ranking.
One practical refinement is to separate the scoring into must-have thresholds and preference weights. A building that cannot deliver 150-amp three-phase power to a wet lab floor fails on a must-have; no preference score can compensate. Must-have screening happens before weighting. Preference weighting governs the comparison of buildings that have cleared the threshold test.
This keeps the evaluation auditable and the rationale connected to the original brief rather than reconstructed after the fact.
Evaluating Technical Specifications in Candidate Buildings
For a life sciences company, building specification diligence goes well beyond what a standard lease due diligence checklist covers. The property team needs to work closely with a lab planner or MEP engineer to assess what the building can actually support versus what the landlord's brochure claims.
Power is typically the first gating question. A modern wet lab environment commonly requires three to six watts per square foot for general research, rising significantly for computational or imaging-intensive programs. The team should confirm available transformer capacity, the condition of the electrical distribution system, and whether the landlord's claimed capacity is already committed to other tenants. Getting a confirmed load letter from the utility is better than relying on a broker representation.
HVAC is equally critical. Life sciences labs typically require six to twelve air changes per hour or more, depending on the hazard classification, and the exhaust system must be designed to prevent re-entrainment of laboratory air into the occupied floors. Buildings originally designed for office use frequently cannot be converted to full wet lab use at a reasonable cost because the mechanical shaft space does not exist to accommodate the exhaust volume.
Slab-to-slab height matters because lab casework, equipment, and exhaust stacks eat vertical clearance faster than in office environments. Twelve feet slab-to-slab is generally considered a workable minimum for a single-story wet lab conversion; anything below that triggers a conversation with the MEP engineer about whether the program can be delivered at all within the existing envelope.
Structuring Lease Economics for Research Stage Companies
Once a building clears the technical threshold, the negotiation shifts to economic structure. Research-stage life sciences companies have specific vulnerabilities in lease negotiation that a generic commercial tenant does not face. Capital is consumed by science, not operations, which means the company needs maximum upfront landlord investment in the space and maximum flexibility to restructure if a program outcome changes the business plan.
The tenant improvement allowance negotiation is therefore not a line item — it is a strategic priority. Lab build-out costs routinely run two to four times the cost of a comparable office build-out, because of the mechanical, electrical, and plumbing complexity. The gap between what a landlord will fund as a standard allowance and what a full lab build-out actually costs represents capital the company must find elsewhere, typically from the science budget.
Effective rent analysis should model the full economic cost over the lease term, including rent abatement, the amortization cost of any overage above the allowance, and the annual escalations that compound over a multi-year term. A lease with a higher face rent but a larger allowance may produce a lower effective cost than a cheaper-looking lease with a thin allowance. Lease net present value modeling — discounting all future cash flows at the company's hurdle rate — converts these alternatives into a comparable number.
Expansion rights deserve careful drafting. A right of first offer on contiguous space is useful only if the trigger event — the landlord receiving a third-party offer — is clearly defined and the company's response window is long enough to obtain board approval. A right of first refusal on a specific suite is more protective but harder to negotiate. Both rights should be evaluated against the company's realistic expansion timeline, which may be shorter than the initial lease term if a Phase 2 readout is expected within three years.
Designing the Portfolio for Multiple Scenarios
A single-site strategy is appropriate for an early-stage company, but once a life sciences organization reaches the point of managing multiple programs across multiple platforms — say, a small molecule and a biologics program simultaneously — multi-site portfolio strategy becomes a practical necessity rather than a growth aspiration.
Multi-site design starts with a clustering decision: does the company want all programs in one market, or does talent availability, partnership geography, or regulatory preference argue for a secondary market? Clustering concentrates management attention and reduces travel cost but creates single-point-of-failure risk if the primary market becomes capacity-constrained or significantly more expensive. A secondary site hedges that risk but requires a management model that works across distance.
Scenario planning is the right tool for multi-site design. Build three operating scenarios: a base case that assumes programs advance at plan, a downside that assumes one major program does not survive its next data readout, and an upside that assumes an unexpected partnership or licensing deal requires rapid capacity addition. For each scenario, model the square footage requirement, the timing of need, and the lease actions required — expansion, contraction, sublease, or new execution. The spread across the three scenarios defines the optionality budget: how much extra space, how many options, and how much financial flexibility the company should build into its portfolio structure today.
The portfolio-strategy layer should also identify critical dates across all leases — expirations, option exercise deadlines, rent step dates, and landlord recapture rights. Missing an option exercise window can cost a company its best space at the moment it needs to expand; missing a recapture notice can lock it into space it no longer needs. These dates should be owned by named individuals with clear accountability, not filed in a lease abstract that no one reads until a crisis arises.
Managing Lease Execution and Diligence
With a preferred site identified and a term sheet agreed, the process shifts to lease execution and formal due diligence. For life sciences, this phase carries additional complexity because the lease document must address laboratory-specific provisions that standard commercial leases do not always include.
Hazardous materials provisions are among the most consequential. The lease should clearly define which materials are permitted, what notification obligations apply to the landlord, and who bears liability for remediation if a spill occurs. Research operations often require solvents, biological agents, and radioactive materials at varying biosafety levels; if the lease's permitted use clause does not accommodate the actual research program, the company may find itself in technical default without realizing it.
HVAC maintenance and air exchange obligations must be clearly allocated. In multi-tenant lab buildings, each tenant's exhaust system interacts with the building's shared mechanical infrastructure. The lease should specify who maintains the exhaust fans serving the tenant's space, who bears the cost of HVAC modifications required by a change in the tenant's research activities, and how disputes about competing exhaust loads are resolved.
The work letter — the document that governs the build-out process — deserves as much negotiation attention as the base lease. It should specify the landlord's design approval timeline, the construction contractor selection process, the payment schedule for the allowance, and the completion date obligations with remedies for delay. A poorly drafted work letter can expose the company to construction delays that push occupancy past the point when the science needs the space.
This matters in life sciences because lease negotiations often involve the executive team, scientific leadership, finance, and external counsel, all reviewing versions of the same document.
Integrating Regulatory and Compliance Factors into Space Planning
Regulatory compliance shapes the physical configuration of life sciences space in ways that purely commercial tenants never encounter. For any company conducting GxP activities — whether GLP for preclinical work or GMP for manufacturing — the facility itself is part of the regulatory submission.
GxP-classified space requires documented evidence of design qualification, installation qualification, and operational qualification for every major building system. The HVAC validation package alone can run to hundreds of pages. This means that when a company selects a space that has previously been used for GxP activities by another tenant, it must verify whether the prior qualification documentation is transferable, and whether any modifications made by the prior tenant or the landlord have been captured in the as-built record.
Biosafety level classification affects the physical configuration of the lab in terms of access control, decontamination protocols, waste stream management, and emergency egress. A BSL-2 space and a BSL-3 space have materially different physical requirements, and a company planning to conduct higher-classification work should confirm that the building's shell can accommodate the required modifications before signing a lease.
Drug Enforcement Administration scheduling requirements apply to companies working with controlled substances, adding a layer of physical security requirement — controlled-access cages, electronic entry logs, and inventory tracking systems — that affects both the space design and the landlord's willingness to accept the use. These requirements should be disclosed early in the negotiation; discovering them after a letter of intent is signed creates friction and sometimes kills a deal entirely.
Building the Portfolio Oversight Infrastructure
Once leases are executed and the portfolio grows beyond two or three sites, ad hoc lease management becomes a significant operational risk. The portfolio oversight infrastructure needs to formalize the processes that were handled informally at single-site stage.
The lead time required to act on each date must be clearly defined, and alerts should be set well ahead of each deadline. The lead time must account for the decision process: a renewal option that requires board approval needs a longer runway than one that the CFO can execute unilaterally.
Translating that aggregate figure into a percentage of company burn rate makes real estate cost visible as a line item in the cash management conversation, rather than allowing it to accumulate invisibly until a lease renewal negotiation reveals the true total.
Preparing for Growth Inflection Points
The most challenging moments in a life sciences company's real estate history come at growth inflection points: a successful Series B that funds a team doubling, a Phase 2 readout that triggers partnership discussions, or an acquisition that adds a legacy footprint overnight. Each of these events renders the existing portfolio strategy partially obsolete and demands rapid reassessment.
A standing portfolio review cadence — typically quarterly — is the best preparation for managing inflection points. This cadence ensures that the real estate team is part of the scientific and financial planning conversation, not a reactive function that hears about a headcount doubling after the hiring plan has already been approved.
Pre-negotiated options are a structural tool for managing inflection risk. If the current landlord has adjacent space available, a right of first offer negotiated at lease signing gives the company a head start on securing it before the market does. If the company expects to need GMP manufacturing space within four years, beginning the site search now — even without a firm plan — means the team understands the available inventory, knows which landlords are willing to fund specialized build-out, and can move decisively when the milestone triggers the need.
Advisers who specialize in life sciences tenant representation bring significant value at inflection points because they maintain ongoing relationships with the landlords and developers who control specialized inventory. Off-market access matters in cluster markets like Boston, San Francisco, San Diego, and Research Triangle, where purpose-built lab supply can be scarce relative to demand during peak periods. Engaging a specialized adviser before the need becomes urgent is better than competing in a heated market without institutional relationships.
Evaluating Build-to-Suit and Ownership Alternatives
As a life sciences company scales toward commercialization, the lease-versus-own question eventually enters the portfolio strategy conversation. The analysis is not simply a lease NPV versus purchase cash flow comparison; it must account for the strategic flexibility implications of ownership, the capital cost, and the management distraction of owning real estate while managing a drug development pipeline.
A build-to-suit arrangement can offer the middle path: purpose-built space designed to the company's exact technical specifications, funded by a developer who retains ownership, with a long-term lease that gives the company site control and the economics of a ground-up build without the balance sheet consequences of ownership. The trade-off is lease term — build-to-suit leases are typically fifteen to twenty years, which is a long commitment for a company whose scientific program may look very different in a decade.
Ownership makes more sense when the company has reached a scale at which the real estate is a strategic asset in its own right — a manufacturing campus that represents competitive differentiation, or a headquarters site that anchors a talent recruitment strategy in a specific market. At that scale, the financial analysis should model multiple scenarios using a full discounted cash flow framework, including the residual value of the asset, the tax treatment of depreciation, and the opportunity cost of the capital that would otherwise go into the science budget.
About Advantai
Advantai is a commercial real estate intelligence and operations platform operated by ADVANTAGE AI LLC, a Delaware limited liability company. It connects client relationships, property research, documents and financial decisions in one workspace for commercial real estate teams — advisers and brokerage teams, occupier and facility teams, and portfolio teams. The platform covers CRM and origination, requirements and site selection, Property X-Ray (an interactive 3D building workspace), financial modeling and comparison, document intelligence, transactions and diligence, client collaboration, and portfolio strategy with critical dates. The optional Super Agent upgrade adds specialist, source-backed research and automated scenario analysis.
Get Started with Advantai
Ready to see your next move clearly? Go to advantaico.com, click Request a demo and tell us about your next project. Prefer to start with a single project? Visit advantaico.com/getting-started to plan your first one.